Tracing new atherogenic properties of PCSK9: Another insight into the pathogenesis of atherosclerosis ‘the Minotaur's labyrinth’
Open Access
- 1 March 2019
- journal article
- editorial
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 60 (2) , 129-130
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart StudyJournal of the American Heart Association, 2017
- The FOURIER study: The profound study of Nature is the most fertile source of discoveryHellenic Journal of Cardiology, 2017
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration and Risk of Cardiovascular Events ― Systematic Review and Meta-Analysis of Prospective Studies ―Circulation Journal, 2017
- Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysisAtherosclerosis, 2016
- Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol loweringCardiovascular Research, 2016
- PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questionsHellenic Journal of Cardiology, 2016
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levelsAtherosclerosis, 2012
- Clinical aspects of PCSK9Atherosclerosis, 2011
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003